Medroxyprogesterone acetate (mpa) increases pai-1 secretion from huvec and elevates the plasma-levels of pai-I in-vivo.
Plasma levels of tissue type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) in patients administered with medroxyprogesterone acetate (MPA) (800 mg/day) or tamoxifen (20 mg/day) were assayed. Active free PAI-1 levels of patients given MPA were significantly higher than those either given tamoxifen or post adjuvant therapy, t-PA antigen levels were not different among the three groups. In in vitro study, treatment of cultured human umbilical vein endothelial cells (HUVEC) with MPA (10(-6)-10(-8) M) decreased PAI-1 levels significantly with a trend to decrease in t-PA levels.